34results about How to "Improve lipid metabolism disorder" patented technology

The invention discloses lactobacillus rhamnosus CCFM1060, a fermented food and a preparation method of a bacterial agent; increase of the abundance of Proteus induced by high lipid and high cholesterol diet is significantly reduced, and the occurrence of diseases such as urinary tract blockage, intestinal bacterial migration and enteritis is reduced; the lipid metabolism disorder of NAFLD patientsis significantly improved; insulin resistance of NAFLD mice is significantly improved; increase of glutamic-pyruvic transaminase and glutamic-oxalacetic transaminase in serum can be re-adjusted; theconcentration of low-density lipoprotein cholesterol is significantly reduced, and the risk of cardiovascular disease is reduced; the level of SOD in liver of NAFLD patients can be significantly improved; the inflammation of liver can be significantly improved; the damage of liver tissues of the NAFLD patients can be significantly improved; the expression of an Nrf2 gene in fatty liver cells can be significantly improved; the ability to absorb perfluorooctanoic acid in vitro is strong.

The invention relates to a method for preparing salvia miltiorrhizae phenolic acid and its new application in medicine production field. The method comprises following steps: adding water or alcohol into salvia miltiorrhizae for extraction, purifying phenolic acid through column chromatography and purification; washing with alcohol solution, condensing washing solution; adjusting pH, extracting with organic solvent, condensing and drying, getting salvia miltiorrhizae phenolic acid with salvia miltiorrhizae phenolic acid A and B content being above 90%. It is proven by medical effect and pharmacological research that the salvia miltiorrhizae phenolic acid can be used to prepare medicine that treats type-2 diabetes and its complication, including diabetes kidney disease, hepatic disease, and blood rheological property change caused by diabetes. It is tested that the effect of salvia miltiorrhizae phenolic acid and its preparation is strong, and they are safe medicine.

The invention provides a traditional Chinese medicine composition for treating diabetic nephropathy. The traditional Chinese medicine composition comprises the following components of Ramulus euonymi, trichosanthes root, Panax pseudo-ginseng var. notoginseng and rhizoma coptidis according to the proportion by weight of 1-3:1-2:1-2:1-3. When being taken, the four medicines are respectively smashed and mixed, decocted by a traditional Chinese medicine decocting method and filtered, and the filtered liquid medicine is taken.

The present invention discloses anti-aging yoghurt containing modified starch and a preparation method thereof. The anti-aging yoghurt containing the modified starch comprises the following raw materials in parts by weight: 40-100 parts of bovine colostrum, 10-30 parts of fish collagen peptide powder, 1-5 parts of a thickener, 2-6 parts of concentrated fruit juice, 0.5-1.5 parts of tea polyphenol nanoparticles, 0.1-1 part of a sweetener and 0.1-1 part of probiotics. The thickener is composed of sodium alginate and modified starch according to a mass ratio of 1:(4-6). The anti-aging yoghurt containing the modified starch is rich in nutrients, delicate in mouthfeel, smooth and refreshing, has effects of regulating balance of human body intestinal micro-ecology, improving intestinal functions, lowering blood lipids and lowering blood pressure, enhancing human body immunity and delaying aging, and is simple and easy to implement in the preparation method, strong in operability, low in cost and suitable for factory production applications.

The invention discloses a medicine for treating fatty liver and hyperlipidaemia and a preparation process thereof. The medicine preparation is prepared from ginseng, silybum marianum, salvia miltiorrhiza and hawthorn by the scientific preparation process and can be used for treating fatty liver diseases. The medicine is characterized in that the pure traditional Chinese medicines are selected and prepared into the preparation, and the medicine has the effects of tonifying heart and kidney, tonifying liver and strengthening spleen and stomach, and can adjust the functions of Qi and blood of human viscera, reinforce Qi and nourish blood, and quite spirit and stabilize mind, aiming at realizing the health function of improving sleeping with the coordination of a plurality of links. The medicine has the advantages of being small in toxic and side effects, treating both symptoms and root causes, and being obvious in treatment effect, fast to remove clinical symptoms, and no relapse after curing.

The invention discloses application of a hydrogen molecule solid carrier in preparation of medicine for preventing and treating obesity related metabolic inflammation. According to the hydrogen molecule solid carrier, molecular hydrogen achieves a physiological effect, the carrier does not achieve the physiological effect, the reducing effect of hydrogen can be fully achieved, and prevention and treatment of obesity related metabolic inflammation are achieved from multiple levels. The application includes the steps of inhibiting increase of serum inflammatory factors in the generating process of obesity related metabolic inflammation, inhibiting increase of adipose tissue inflammatory factors, relieving adipose tissue dyslipidemia, inhibiting generation of oxidative damage in adipose tissue and inhibiting activation of inflammasome in the adipose tissue. The result shows that the hydrogen molecule solid carrier is fairly effective medicine for preventing and treating obesity related metabolic inflammation.

The invention relates to a kiwi fruit extract and an extraction method and an application thereof. The extraction method of the kiwi fruit extract includes that fresh kiwi fruits with skins are cut up, the cut fresh kiwi fruits are heated by methanol and subjected to reflux extraction for two times, the first time of the reflux extraction is performed for 1.5 hours to 2.5 hours, the second time of the reflux extraction is performed for 0.5 hour to 1.5 hours, the twice extracting solutions are combined, filtered and concentrated to obtain a kiwi fruit methanol total extract, the kiwi fruit methanol total extract is subjected to extraction by petroleum ether, ethyl acetate and n-butyl alcohol sequentially, and after reduced pressure suction filtration and concentration, a kiwi fruit petroleum ether extracting part, an ethyl acetate extracting part and an n-butyl alcohol extracting part are respectively obtained. According to internal experiment, acarbose serves as positive control, the therapeutic effect of the kiwi fruit petroleum ether, the ethyl acetate and the n-butyl alcohol extracting parts on a diabetic mouse which is induced by alloxan is observed, and the experimental result shows that a certain therapeutic effect of kiwi fruit ACPE, ACEA and ACBU on the diabetic mouse which is induced by the alloxan is achieved.

The invention discloses an application of ginsenoside CK and Rh1 and a composition thereof in preparation of medicine for improving non-alcoholic fatty hepatic fibrosis and insulin resistance, and relates to a medical application of the ginsenoside CK and Rh1 and the composition thereof. According to the application, in-vitro and in-vivo studies show that the ginsenoside CK and Rh1 and the composition thereof can regulate and control synthesis and degradation of epimatrix of hepatic stellate cells (HSC-T6) of mice, significantly improve the abnormal liver function, lipid metabolism disorders, abnormal glucose metabolism and hepatic fibrosis degree of the non-alcoholic fatty hepatic fibrosis mice, and has a development prospect for serving as the medicine of combination of non-alcoholic fatty hepatic fibrosis and insulin resistance.

The invention discloses a human secretory FNDC5 protein as well as a preparation method and application thereof, and relates to the technical field of gene engineering. The human secretory FNDC5 protein does not contain a transmembrane structural domain and can be directly secreted and released into blood. The human secretory FNDC5 protein can be used for preparing medicines for treating atherosclerosis, medicines for promoting bone formation and medicines for treating aplastic anemia, and can be used for preparing endothelial cell proliferation medicines. After fasting injection is conductedon a high-fat fed obese mouse model, the human secretory FNDC5 protein can effectively reduce the weight of an obese mouse, which shows that the protein can obviously improve body fat metabolism of anobese patient and obviously reduce the levels of plasma cholesterol, free fatty acid and triglyceride, and shows that the protein can obviously improve lipid metabolism disorder of the obese patient.

A composition for prevention and treatment of metabolic syndromes is composed of radix astragali preparata, rhizoma polygonati, mulberry fruits, yam, fructus crataegi, lotus leaves, cassia seeds, phaseolus calcaratus, poria cocos, endothelium corneum gigeriae galli, fructus amomi, dandelions and the like. It is verified that the composition has the functions of relieving and preventing the metabolic syndromes such as abdominal obesity, dyslipidemia and abnormal glucose metabolism.

The invention relates to a method for using soft-shelled turtle ovum to prepare the drug that treats diabetes and reduce blood sugar, wherein soft-shelled turtle ovum comprises protein, unsaturated fatty acid, Omega-3 multi unsaturated fatty acid (EPA, DHA), and anti-oxidization nutrient (vitamin E), etc. the test has proves that: the diabetes mouse caused by alloxan that eats said drug can reduce blood sugar and release high triglyceride content and high cholesterol content. The invention can significantly treat fatty metabolic disorder, etc.

The invention discloses a secretion-type FNDC5 protein. The secretion-type FNDC5 protein does not contain a transmembrane domain and can be directly secreted and released into blood; and the amino acid sequence of the FNDC5 protein is SEQ ID NO:1. The secretion-type FNDC5 protein is simple in structure and convenient to obtain. The secretion-type FNDC5 protein can be used for treating obesity-related metabolic disorders; after the secretion-type FNDC5 recombinant protein is injected into the abdominal cavity of a high-fat fed obese mouse model, glucose and insulin tolerance can be effectivelyimproved, and it shows that the protein can obviously relieve glucose metabolic disorders and insulin resistance of obese patients; and fatty liver occurrence can be obviously relieved, the level of plasma cholesterol, free fatty acid and triglyceride is decreased, and it shows that the protein can relieve the lipometabolic disorders of the obese patients. The secretion-type FNDC5 protein can serve as a new drug target for treating the metabolic disease to be developed.

The invention relates to a fat-reducing composition. The fat-reducing composition contains the following raw materials in parts by weight: 30-40 parts of aronia melanocarpa fruit juice powder, 10-20 parts of medium chain triglyceride micro-capsule powder, 10-20 parts of towel gourd powder, 3-13 parts of Akkermansia muciniphila and 10-20 parts of fructo-oligosaccharide. The medium chain triglyceride micro-capsule powder and the aronia melanocarpa fruit juice powder in the fat-reducing composition are compounded so as to burn fat, inhibit fat synthesis and reduce accumulation of the fat in a human body, so that a synergetic fat-reducing effect is achieved; by virtue of synergism of Akk bacteria and the towel gourd powder, intestinal florae are regulated, and an effect of controlling the bodyweight is achieved; by virtue of synergism of polyphenol in the aronia melanocarpa fruit juice powder and the fructo-oligosaccharide, the abundance of the Akk bacteria is increased, and a fat-reducing effect is achieved. By integrating the effects of the five components, the fat-reducing composition is reasonable in compatibility, safe and effective; and the components generate a synergistic effect in different ways, so that the burning of the fat is accelerated, the intestinal florae are regulated, and the fat-reducing effect is relatively efficient.

The present invention discloses a functional food using apple pectin as main component to regulate blood sugar and preparation method thereof which is a food to regulate blood sugar reaction for diabetes patient, a functional food prepared by the combination of the main materials of apple pectin and other functional trace elements. The invention is characterized in that it is composed of the following components: apple pectin of 35-75%, chromium picolinate of 0.0015-0.03%, zinc lactate of 0.227-0.453%, sodium selenite of 0.00037-0.00075%, sorbitol of 19.5-60.5% and hydroxypropyl methylcellulose of 1-10%; is prepared by the processing steps of combination, granulating, drying, sizing, packaging and the like into granular formulation, and is a functional food with simple preparation method, convenient use and capability of effectively preventing and treating diabetes and relative complications.

The invention provides a lactobacillus plantarum Q16 capable of relieving non-alcoholic fatty liver function caused by high fat diet, the classification name of the lactobacillus plantarum is lactobacillus plantarum, the lactobacillus plantarum is preserved in China Center for Type Culture Collection on October 22, 2021, the address is Wuhan University, Wuhan, China, the postcode is 430072, and the preservation number is CCTCC NO: M20211311. The strain can effectively reduce the body weight, liver weight and fat weight of a high-fat diet mouse, improve lipid metabolism in the liver, inhibit accumulation of triglyceride and improve energy metabolism in the liver; in addition, the strain also has the capability of optimizing the intestinal flora structure, and has a good probiotic function.

The invention discloses an application of formononetin to treatment of nonalcoholic fatty liver disease. An in vitro and an in vitro cell model are adopted, formononetin is used for treating animals,and the improvement effect of the formononetin on metabolic syndromes of nonalcoholic fatty liver, obesity, insulin resistance, lipid disorders and the like can be observed. Experiment proves that theformononetin can notably reduce weight, liver weight / body mass indexes, liver triglyceride(TG), liver lipidoses, liver function damage criterion-millet straw aminopherase (AST) and alanine aminotransferase (ALT) of organisms suffering from nonalcoholic fatty liver, and besides, can improve insulin resistance. Blood biochemistry detection indicates that the formononetin can also reduce the level of triglyceride (TG), cholesterol (TC) and low intensity lipoprotein (LDL-C) of HFD mice, and can improve the lipid disorders. The formononetin has important effects on treatment of nonalcoholic fattyliver.

The invention discloses digestive yogurt containing modified starch and a preparation method thereof. The yogurt is prepared from the following raw materials in parts by weight: 80-120 parts of bovinecolostrum, 1-5 parts of the modified starch, 2-6 parts of fruit juice concentrate, 0.1-1 part of a sweetening agent, 0.1-1 part of probiotics and 0.5-1.5 parts of prebiotics, wherein the modified starch is composed of corn modified starch, cassava modified starch and potato modified starch according to a mass ratio of 1 to (3 to 5) to 2. The digestive yogurt containing the modified starch disclosed by the invention is rich in nutrition, and delicate and smooth in mouthfeel, has the functions of regulating the balance of human intestinal microecology, improving intestinal function, aiding digestion, reducing lipids and blood pressure, enhancing human immunity, and resisting aging, and is suitable for children, the aged and diabetics to eat; meanwhile, the preparation method of the yogurt is simple and practicable, strong in operability, low in cost, and is suitable for industrialized production and application.

The invention relates to the field of health-care food, in particular to grease for preventing complications of cardiovascular diseases of diabetes mellitus, and the ratio of n-6 to n-3 PUFA of the grease is (4.5-5.5) 1. The grease can be applied to preparation of medicines for preventing complications of cardiovascular diseases of diabetes mellitus, or can be applied to preparation of health foodfor preventing complications of cardiovascular diseases of diabetes mellitus. As a diet, common symptoms of diabetic mice can be improved. Diet with the ratio of n-6 to n-3 PUFA being 4.5-5.5 1 increases the weight of diabetic mice, and the weight of the long-term intervention group and the weight of the intermittent intervention group are increased by 3.21% and 4.00% compared with a control group. As diet intervention, the composition can improve lipid metabolism disorder, reduce lipid deposition, significantly reduce AI and prevent diabetic cardiovascular disease complications.

The invention provides a use of Berberis dasystachya Maxim. fruit polysaccharide in preparation of drugs, health products or foods for improving dyslipidemia. A research proves that Berberis dasystachya Maxim. fruit can improve dyslipidemia, reduce cholesterol (TC), triglyceride (TG) and low density lipoprotein (LDL), increase high density lipoprotein (HDL), improve dyslipidemia-related enzyme activity thereby improving lipoprotein lipase and hepatic lipase activity, reduce glutamic oxalacetic transaminase and glutamic-pyruvic transaminase activity, does not damage liver tissue, and can be used as a drug, a health product or a food used for improving dyslipidemia and having good safety.

The invention relates to the lipid-lowering field of kaempferol-3-O-rutinoside, and relates to application of kaempferol-3-O-rutinoside to preparation of PCSK9 (Proprotein convertase subtilisin / kexintype 9) target inhibition medicine. Kaempferol-3-O-rutinoside is firstly found to have specific activity for inhibiting the binding of PCSK9 to LDLR (Low-Density Lipoprotein Receptor), can be subjected to affinity binding with an active pocket area of a PCSK9 crystal structure, and form stable hydrogen bonds with a plurality of amino acid residues, thereby being a novel small molecule inhibitor for PCSK9. The kaempferol-3-O-rutinoside can reduce the levels of TC (Total Cholesterol), TG (Triglyceride) and LDL-C (Low-Density Lipoprotein Cholesterol) in plasma of hyperlipidemia model mice, and improve the level of HDL-C (High-Density Lipoprotein cholesterol). The kaempferol-3-O-rutinoside has the effect of alleviating lipid metabolism disorder of hyperlipidemia and can be used for preventingor treating cardiovascular diseases (including the hyperlipidemia).

The invention discloses composition containing salvia miltiorrhiza fat soluble ingredients and coenzyme Q10, a preparation method of the composition and a drug containing the composition. The composition is prepared from components in percentage by weight as follows: 8%-24% of the salvia miltiorrhiza fat soluble ingredients, 16%-23% of the coenzyme Q10, 1.2%-3% of vitamin K and 50%-74% of corn oil. The composition can correct lipid metabolism unbalance of a body, reduce generation of lipid peroxide and reduce activation of inflammatory factors, so that atherosclerosis of aorta and cognitive impairment are relieved, and the composition has the efficacy of relieving disturbance of lipid metabolism, promoting antioxidation, relaxing vascular smooth muscles, repairing vascular endothelial cells and preventing nerve cell injury caused by ischemia and hypoxia; besides, the composition is used for preparing the drug and can effectively prevent or / and treat cardiovascular diseases and vascular dementia.

The invention discloses a human-derived secreted FNDC5 protein and its preparation method and application, and relates to the technical field of genetic engineering; wherein the human-derived secreted FNDC5 protein does not contain a transmembrane domain, and can be directly secreted and released into blood; The human-derived secreted FNDC5 protein of the invention can be used for preparing medicines for treating atherosclerosis, promoting bone formation and treating aplastic anemia, and can prepare medicines for proliferation of endothelial cells. The human-derived secreted FNDC5 protein of the present invention can effectively reduce the body weight of obese mice after fasting injection to obese mouse models fed with high fat, indicating that the protein can significantly improve body fat metabolism of obese patients, significantly reduce plasma cholesterol, The levels of free fatty acids and triglycerides indicate that the protein can significantly improve lipid metabolism disorders in obese patients.

The invention discloses vermicelli suitable for people with metabolic syndrome, and a preparation method of the vermicelli, belonging to the field of food processing. The vermicelli is prepared by taking barley flour fermented by using lactobacillus plantarum, and wheat flour as raw materials, wherein edible salt, edible sodium carbonate and vital gluten are added into the raw materials; the preparation method comprises the processes of kneading dough, carrying out curing calendering, carrying out secondary curing calendering, cutting into strips, drying in the air, packaging, and the like. The vermicelli is prepared by taking barley, which has rich nutritional value and prominent health care functions, as one raw material, and the barley is dried into powder after being fermented by using the lactobacillus plantarum, so that the biological transformation of nutrient substances is realized, and the vermicelli can help the people with the metabolic syndrome to lose weight and relieve the glucose and lipid metabolism disorder of the people with the metabolic syndrome after being eaten for a long time. The vermicelli realizes the complementary advantages of the barley flour fermented by using the lactobacillus plantarum, and the wheat flour, so that the barley flour fermented by using the lactobacillus plantarum supplements partial nutrients such as beta-glucan, phenolic compounds and mineral substances which are lacked by the wheat flour on the one hand, and rich gluten and excellent processing performance of the wheat flour make up the defect that the barley flour fermented by using the lactobacillus plantarum cannot easily form a gluten structure on the other hand. Furthermore, in the process of fermenting the barley flour by using the lactobacillus plantarum, functional polypeptide is formed by means of proteolysis, so that a contribution is made to the use of the vermicelli.

The invention discloses an application of ginsenoside CK and Rh1 and a composition thereof in preparation of medicine for improving non-alcoholic fatty hepatic fibrosis and insulin resistance, and relates to a medical application of the ginsenoside CK and Rh1 and the composition thereof. According to the application, in-vitro and in-vivo studies show that the ginsenoside CK and Rh1 and the composition thereof can regulate and control synthesis and degradation of epimatrix of hepatic stellate cells (HSC-T6) of mice, significantly improve the abnormal liver function, lipid metabolism disorders, abnormal glucose metabolism and hepatic fibrosis degree of the non-alcoholic fatty hepatic fibrosis mice, and has a development prospect for serving as the medicine of combination of non-alcoholic fatty hepatic fibrosis and insulin resistance.

The invention discloses a medicine for treating fatty liver and hyperlipidaemia and a preparation process thereof. The medicine preparation is prepared from ginseng, silybum marianum, salvia miltiorrhiza and hawthorn by the scientific preparation process and can be used for treating fatty liver diseases. The medicine is characterized in that the pure traditional Chinese medicines are selected and prepared into the preparation, and the medicine has the effects of tonifying heart and kidney, tonifying liver and strengthening spleen and stomach, and can adjust the functions of Qi and blood of human viscera, reinforce Qi and nourish blood, and quite spirit and stabilize mind, aiming at realizing the health function of improving sleeping with the coordination of a plurality of links. The medicine has the advantages of being small in toxic and side effects, treating both symptoms and root causes, and being obvious in treatment effect, fast to remove clinical symptoms, and no relapse after curing.

The invention discloses a secretion-type FNDC5 protein. The secretion-type FNDC5 protein does not contain a transmembrane domain and can be directly secreted and released into blood; and the amino acid sequence of the FNDC5 protein is SEQ ID NO:1. The secretion-type FNDC5 protein is simple in structure and convenient to obtain. The secretion-type FNDC5 protein can be used for treating obesity-related metabolic disorders; after the secretion-type FNDC5 recombinant protein is injected into the abdominal cavity of a high-fat fed obese mouse model, glucose and insulin tolerance can be effectivelyimproved, and it shows that the protein can obviously relieve glucose metabolic disorders and insulin resistance of obese patients; and fatty liver occurrence can be obviously relieved, the level of plasma cholesterol, free fatty acid and triglyceride is decreased, and it shows that the protein can relieve the lipometabolic disorders of the obese patients. The secretion-type FNDC5 protein can serve as a new drug target for treating the metabolic disease to be developed.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition and application thereof. The invention relates to a new application of a traditional Chinese medicine composition developed on the basis of a patent ZL200410073958. X. The traditional Chinese medicine composition is mainly prepared from immature bitter orange, bighead atractylodes rhizome, ginseng, wolfberry fruit, donkey-hide gelatin, fleece-flower root, cassia seed and aloe. The traditional Chinese medicine composition can effectively reduce the levels of ALT, AST, GLB, TP, TC, TG and LDL-C in serum of a non-alcoholic fat rat induced by high fat diet and the content of MDA in the liver, and improve the levels of HDL-C and A / G in the serum and the activities of SOD, GSH and GSH-Px in the liver.

The invention provides tangut barberry bark fruit polysaccharide which is an extract from a Berberis dasystachya Maxim. fruit; the polysaccharide content of the extract is 60-95% w / w. Researches show that tangut barberry bark fruit polysaccharide has a favorable blood glucose reducing function, can increase the insulin amount, and has a certain adjusting effect on the activities of corresponding ROS metabolism related enzymes such as superoxide dismutase, catalase and glutathione peroxidase. Besides, the effect of the high dose group of a tangut barberry bark fruit is equivalent to that of glibenclamide, while though glibenclamide is a chemical drug for treating diabetes, taking of a large amount of glibenclamide for a long time can cause hypoglycemia and nephropathy finally, or even death; otherwise, the tangut barberry bark fruit is an edible berry, is favorable in safety, and is more suitable for being used as a food, a health product or a drug for treating and preventing diabetes.

The invention relates to the field of lipid reduction based on Kaempferol 3-O-2''-(6'''-p-coumaroyl) glucosylrhamnoside (KCGR) and discloses application of the KCGR in preparation of drugs capable ofinhibiting PCSK9 targets. It is discovered for the first time that the KCGR has the specificity of inhibiting the combination activity of PCSK9 and LDLR and can be compatibly combined in an active pocket area of a PCSK9 crystal structure and form stable hydrogen bonds with multiple amino acid residues, and therefore the KCGR is a novel micromolecular inhibitor for the PCSK9. The KCGR can lower thelevel of TC, TG and TDL-C in plasma of a hyperlipidaemia model mouse and raise the level of HDL-C, has the effect of alleviating lipid metabolism disorder caused by hyperlipidaemia and can be used for preventing or treating cardiovascular diseases and hyperlipidaemia.